Pharma Focus Europe

Celanese and Secarna Pharmaceuticals Collaborate on RNA Research for Prolonged Antisense Therapies

Thursday, March 21, 2024

Celanese Corporation, a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, an independent European antisense drug discovery and development company, have announced a collaboration. They aim to develop long-acting implants delivering antisense oligonucleotides (ASOs).

ASOs are synthetic molecules targeting specific messenger RNA, preventing protein production linked to various diseases. However, current ASO therapies often require frequent dosing or large doses, posing challenges for patients.

The partnership combines Celanese's VitalDose® Drug Delivery Platform with Secarna's ASO Drug Discovery and Development Platform. The goal is to create ASO-eluting implants to reduce dosing frequency, minimize immune responses, and improve targeting accuracy.

Cyonna Holmes, Celanese's global business strategy leader for Ophthalmology and RNA, expressed excitement about the collaboration's potential. Konstantin Petropoulos, CBO of Secarna Pharmaceuticals, also emphasized the opportunity to enhance ASO therapy delivery.

The collaboration includes joint research efforts, including work at Celanese's Development & Feasibility Lab. 



Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024